Redefining Success in Academic Biomedical Innovation: Evaluating Programmatic Impact Beyond Commercial Outcomes

Academic biomedical innovation programs play a critical role in advancing translational science, yet their contributions are often assessed primarily through downstream commercialization metrics such as licensing revenue, startup formation or exit, and return on investment.While these indicators remain valuable, they capture only a narrow portion of the value created by programs designed to build translational capacity, support investigator development, and strengthen innovation ecosystems over time.Moreover, such metrics often emerge late in the translational process, limiting their usefulness for timely program adaptation and strategic decision-making.Academic innovation programs should be evaluated using complementary approaches that align with broader goals and operating realities.Drawing on innovation programming at the Oregon Clinical and Translational Research Institute (OCTRI), a Clinical and Translational Science Awards (CTSA) hub, we illustrate how program-level outcomes become visible when evaluation extends beyond project-specific commercial endpoints.We then propose a purpose-built evaluation framework organized around three domains: supporting individual innovators, building a culture of innovation, and strengthening the innovation ecosystem.Applying this framework to OCTRI's innovation programs highlights opportunities for institutional learning, adaptive program design, and sustained translational capacity building.